Ipratropium Bromide Clinical Uses and Guidelines

Primary Respiratory Indications

For acute severe asthma in adults, add ipratropium bromide 500 μg to beta-agonist if initial treatment fails, and consider hospital admission, as recommended by the British Thoracic Society 2, 3
In children with severe asthma, add ipratropium bromide 250 μg at 30 minutes if not improving after initial beta-agonist treatment, according to the British Thoracic Society guidelines 2, 3
Ipratropium provides additive benefit to short-acting beta-agonists in moderate or severe exacerbations in the emergency care setting, as stated by the American Academy of Allergy, Asthma, and Immunology 4
For severe COPD exacerbations, nebulize ipratropium bromide 250-500 μg every 4-6 hours, as recommended by the British Thoracic Society 2, 3
Critical safety point: Do not nebulize with oxygen in COPD patients; use a 24% Venturi mask between treatments, as advised by the British Thoracic Society 2, 3

Ipratropium bromide nasal spray 0.03% is recommended for treating rhinorrhea associated with perennial allergic and nonallergic rhinitis in patients 6 years of age and older, according to the American Academy of Allergy, Asthma, and Immunology 1
Combined use with intranasal corticosteroids is more effective than either drug alone for rhinorrhea, without increased adverse events, as stated by the American Academy of Allergy, Asthma, and Immunology 1
Ipratropium bromide nasal spray 0.06% is approved for rhinorrhea associated with the common cold in patients 5 years of age and older, as recommended by the American Academy of Pediatrics 1
Important limitation: Ipratropium has no effect on nasal congestion; if significant obstruction is present, add intranasal corticosteroids or oral decongestants, as advised by the American Academy of Allergy, Asthma, and Immunology 1

Treat asthma and COPD as per standard adult protocols in elderly patients, as recommended by the British Thoracic Society 2, 3
First treatment should be supervised, as beta-agonists may rarely precipitate angina, according to the British Thoracic Society guidelines 2, 3
Because glaucoma may be worsened by ipratropium, use of a mouthpiece should be considered to prevent ocular exposure, as advised by the British Thoracic Society 2, 3

Most common adverse events are mild transient epistaxis (9% vs 5% with placebo) and nasal dryness (5% vs 1% with placebo) for nasal formulations, as reported by the American Academy of Allergy, Asthma, and Immunology 1
Ipratropium does not alter physiologic nasal functions such as sense of smell, ciliary beat frequency, mucociliary clearance, or the air conditioning capacity of the nose, according to the American Academy of Allergy, Asthma, and Immunology 1

Never use ipratropium as monotherapy for acute asthma exacerbations due to delayed onset of action, as warned by the American Academy of Allergy, Asthma, and Immunology 1
Do not expect improvement in nasal congestion or sneezing with ipratropium; these symptoms require alternative agents (corticosteroids for congestion, antihistamines for sneezing), as advised by the American Academy of Allergy, Asthma, and Immunology 1
Avoid nebulizing with oxygen in COPD patients to prevent CO2 retention, as recommended by the British Thoracic Society 2, 3
Ensure proper mouthpiece technique in elderly patients to prevent ocular exposure and glaucoma exacerbation, as advised by the British Thoracic Society 2, 3